FDA Extends NDA Review for Neuromed Pharmaceuticals's Exalgo(TM) Extended-Release Tablets
11/20/2009 8:31:56 AM
More...
|
CombinatoRx, Incorporated (CRXX) And Neuromed Pharmaceuticals Receive FDA Feedback on New Drug Application for Exalgo Extended-Release Tablets
11/16/2009 9:40:13 AM
More...
|
CombinatoRx, Incorporated (CRXX) and Neuromed Pharmaceuticals Announce Posting of Briefing Documents for FDA Advisory Committee
9/22/2009 9:11:03 AM
More...
|
CombinatoRx, Incorporated (CRXX) to Merge with Privately Held Neuromed Pharmaceuticals
7/1/2009 7:09:59 AM
More...
|
Neuromed Pharmaceuticals Announces Sale of U.S. Rights to Drug Candidate Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) to Mallinckrodt Inc.
6/17/2009 7:26:33 AM
More...
|
Neuromed Pharmaceuticals Announces that Merck & Co., Inc. (MRK) (JOBS) Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
6/11/2009 8:31:08 AM
More...
|
Neuromed Pharmaceuticals Announces Exalgo(TM) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
3/23/2009 7:24:34 AM
More...
|
Neuromed Pharmaceuticals Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
11/20/2008 8:05:02 AM
More...
|
Neuromed Pharmaceuticals's Sean Cunliffe Named to PharmaVOICE's 2008 Top "100 Most Inspiring People in the Life Sciences Industry"
7/23/2008 4:29:26 PM
More...
|
Neuromed Pharmaceuticals Names Sean Cunliffe Chief Commercial Officer
4/29/2008 8:31:49 AM
More...
|
|